Compugen

Compugen is a clinical-stage biotechnology company focused on discovering and developing cancer immunotherapy assets. It uses its Unigen AI/ML-based computational discovery platform to identify novel drug targets and monetize programs through partnerships and licensing arrangements, including a license to Gilead Sciences.

Relationship details are part of the Pro plan.